Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
Clinical trial NCT05584137 · TERMINATED
Trial details
- NCT number
- NCT05584137
- Sponsor
- Shanghai Henlius Biotech
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-15
- Primary completion
- 2023-12-31
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.